Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evotec SE (OTCPK:EVOTF) Q2 2023 Earnings Conference Call August 29, 2023 8:00 AM ET Company Participants Werner Lanthaler - CEO Laetitia Rouxel - CFO Cord Dohrmann - CSO Matthias Evers - Chief Business Officer Conference Call Participants Peter Verdult - Citigroup James Quigley - Morgan Stanley Wolf Chanoff - Bank of America Steven Mah - TD Cowen Joseph Hedden - Rx Securities Charles Weston - RBC Capital Markets Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.

Evotec SE (EVOTF) Q2 2023 Earnings Call Transcript

NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced its financial results and corporate updates for the first half-year of 2023. HIGHLIGHTS Q2 CYBER-INCIDENT TEMPORARILY REDUNCING STRONG ORGANIC REVENUE GROWTH Group revenues increased by 14% to € 383.8 m (H1 2022: € 336.9 m) driven by strong demand for base business and successful partnering activities; like-for-like revenue growth (excluding fx-effects and M&A effects) 14% Total EVT Execute revenues (incl.

Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023

HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 - 790 m (previously € 820 - 840 m); unpartnered R&D is expected in a range of € 60 - 70 m (previously € 70 - 80 m); and the adjusted EBITDA is expected to reach € 60 - 80 m (previously € 115 - 130 m).

Evotec Provides Update on Financial Impact of Cyber-Attack

Bristol-Myers

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALTIES UP TO LOW DOUBLE-DIGIT PERCENTAGES ON PRODUCT SALES HAMBURG, GERMANY / ACCESSWIRE / July 11, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that Bristol Myers Squibb Company (NYSE:BMY) has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration.

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

Evotec's Seattle-based subsidiary has won a $74 million contract with the U.S. Department of Defence to develop monoclonal antibody-based drugs targeting orthopoxviruses, the German biotech firm said on Wednesday.

Evotec wins orthopoxvirus antibody contract from U.S. government

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE NOVO ANTIBODY DESIGN OF THERAPEUTIC CANDIDATES EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANY / ACCESSWIRE / July 5, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that the U.S. Department of Defense ("DOD") has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody ("mAb")-based drug product prototypes targeting orthopoxviruses. Under the contract, Just - Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase I first-in human ("FIH") clinical trials.

Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program

PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / June 29, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody ("mAb") targeting the protein Semaphorin-3A ("Sema3A") is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.

Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme

ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY REPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023 HAMBURG, GERMANY / ACCESSWIRE / June 20, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2023 with the required majority. Under the topic "Ahead of the curve - leading in our four focus areas", Chief Executive Officer Dr Werner Lanthaler and Chief Financial Officer Laetitia Rouxel presented to the Company's shareholders an update and outlook of Evotec's strategic, scientific, and technological developments, as well as the Company's business performance and commitment to a sustainable growth strategy.

Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items

TOGETHER FOR A SUSTAINABLE AND EFFICIENT SHARED R&D ECONOMY PRECISION MEDICINES AND BETTER ACCESS TO BIOTHERAPEUTICS ESG PERFORMANCE REPORT HIGHLIGHTS SUSTAINABILITY AS A COMPETITIVE ADVANTAGE IN CHALLENGING TIMES HAMBURG, GERMANY / ACCESSWIRE / June 5, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, ISIN: DE0005664809; NASDAQ:EVO) today presents an update on the Company's sustainability strategy and shares details on its ESG (Environmental, Social and Governance) performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day. In a rapidly changing world, marked by unexpected opportunities and challenges like climate change but also technical and social changes with far-reaching impacts, a flexible and resilient approach is crucial.

Evotec Presents Sustainability Strategy

$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM HENIPAVIRAL AGENTS ARE PRIORITY PATHOGENS LISTED ON THE WHO'S R&D BLUEPRINT LIST OF EPIDEMIC THREATS NEEDING URGENT R&D ACTION HAMBURG, GERMANY / ACCESSWIRE / June 2, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses.

Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics

PUBLICATION OF ANNUAL REPORT 2022: "AHEAD OF THE CURVE" QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED HAMBURG, GERMANY / ACCESSWIRE / May 12, 2023 / Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809; NASDAQ:EVO) today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023. Evotec's fully audited Annual Report 2022 "Ahead of the Curve" is now available for downloading on www.evotec.com/financial-reports.

Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

HHAMBURG, GERMANY / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. The partnership includes an option for the non-exclusive in-licensing of Just - Evotec Biologics' proprietary J.DESIGN technology by Sandoz to build a state-of-the-art, ‘S.POD' facility fully owned by Sandoz in the latter part of this decade.

Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz

Novartis

JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTION THE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBE THE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAPABILITIES THE PARTNERSHIP INCLUDES AN OPTION FOR SANDOZ TO INLICENSE JUST - EVOTEC BIOLOGICS' FULL TECH STACK, INJECTED IN ITS FULLY-OWNED ‘S.POD' FACILITY TO EXPAND THE DISRUPTIVE DEVELOPMENT AND MANUFACTURING OF BIOSIMLARS IN THE LATTER PART OF THIS DECADE HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT), Prime Standard, ISIN: DE0005664809; (NASDAQ:EVO) and Sandoz AG, a division of Novartis (NASDAQ:NVS) today announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. The partnership includes an option for the non-exclusive in-licensing of Just - Evotec Biologics' proprietary technology by Sandoz for building its fully-owned S.POD facility (in analogy to Just - Evotec Biologics' state-of-the-art J.POD facilities).

Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts HAMBURG, GERMANY / ACCESSWIRE / April 10, 2023 / Evotec SE (FFSE:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual activity in one of the Company's IT systems and immediately took steps to maintain IT security and remediate the impact.

Evotec SE Provides Update on Cyber Attack

HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnected from the Internet to secure from data corruption or breaches.

Cyber Attack on Evotec

A reader asked me to take a look at German company Evotec, which also has a dual listing on NASDAQ under symbol EVO. His question was whether I view the company as a value trap, or as a significantly undervalued stock that I would be open to investing in.

Evotec: Significantly Undervalued, Or Value Trap?

Evotec SE (OTCPK:EVOTF) Q4 2022 Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - Royal Bank of Canada Peter Verdult - Citi James Quigley - Morgan Stanley Steven Mah - Cowen Peter Welford - Jefferies Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining the Evotec SE Preliminary Figures Full-Year 2022 Call.

Evotec SE (EVOTF) Q4 2022 Earnings Call Transcript

8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALES HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE: BMY), originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes.

Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022. FINANCIALS REFLECT GREAT PERFORMANCE Group revenues significantly exceeded the revenue target, up 22% to € 751.4 m (+15% like for like, excluding portfolio and fx effects (2021: € 618.0 m)) Excellent base business up 30% to € 725.3 m in 2022 Adjusted Group EBITDA at € 101.7 m, adjusted for portfolio effects at € 104.1 m (2021: € 107.3 m) after a very strong fourth quarter Unpartnered R&D expenses of € 70.2 m up 20% (2021: € 58.1 m) GREAT PROGRESS AND STRONG DEMAND IN ALL LANES Significant progress in and 8-year extension of targeted protein degradation alliance with Bristol Myers Squibb ("BMS") Important milestones achieved in iPSC-based neuroscience collaboration with BMS Multiple new strategic partnerships e.g.

Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year

GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 "WORLD TUBERCULOSIS DAY", 24 MARCH RAISES PUBLIC AWARENESS ABOUT DEVASTATING HEALTH, SOCIAL AND ECONOMIC CONSEQUENCES OF THE TUBERCULOSIS EPIDEMIC HAMBURG, GERMANY / ACCESSWIRE / March 24, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) announced today that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis ("TB"). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.

Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis

HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023

KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / March 16, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based achievements trigger payments of in total US$ 75 m to Evotec.

Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC TRANSACTION TO BE SIGNED BY EVOTEC'S MANAGEMENT AND EIB VICE PRESIDENT AMBROISE FAYOLLE ON CAMPUS CURIE TODAY HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / February 10, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and the European Investment Bank ("EIB") announced today that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company's R&D activities, equity investments and the building of the new J.POD ® biologics manufacturing facility on Evotec's Campus Curie in Toulouse, France. Through this new financing of € 150 m, the EIB reiterates its supports to Evotec, a company that it already supported in 2017 with a financing of € 75 m.

Evotec Receives € 150 m Loan from European Investment Bank

EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE EVOTEC'S INDUSTRY-LEADING CAPABILITIES IN THE DISCOVERY OF COVALENT INHIBITORS HAMBURG, GERMANY / ACCESSWIRE / February 9, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced today that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences ("RS"), to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec's industry-leading capabilities across the full R&D continuum. Launched in early 2021, the Evotec-RS partnership brings together a unique set of complementary capabilities to efficiently select, discover, and develop new, precisely targeted medicines for unmet patient needs.

News for Evotec SE Stock (EVO)